Doxazosin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
=== | ===Doxazosin<sup>®</sup>=== | ||
''' [[Doxazosin indications and usage|Indications and Usage]]''' | ''' [[Doxazosin indications and usage|Indications and Usage]]''' | ||
'''| [[Doxazosin dosage and administration|Dosage and Administration]]''' | '''| [[Doxazosin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Doxazosin contraindications|Contraindications]]''' | '''| [[Doxazosin contraindications|Contraindications]]''' | ||
'''| [[Doxazosin warnings | '''| [[Doxazosin warnings|Warnings]]''' | ||
'''| [[Doxazosin precautions|Precautions]]''' | |||
'''| [[Doxazosin adverse reactions|Adverse Reactions]]''' | '''| [[Doxazosin adverse reactions|Adverse Reactions]]''' | ||
'''| [[Doxazosin drug interactions|Drug Interactions]]''' | '''| [[Doxazosin drug interactions|Drug Interactions]]''' | ||
| Line 35: | Line 35: | ||
'''| [[Doxazosin clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Doxazosin clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Doxazosin nonclinical toxicology|Nonclinical Toxicology]]''' | '''| [[Doxazosin nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Doxazosin how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Doxazosin how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Doxazosin patient counseling information|Patient Counseling Information]]''' | '''| [[Doxazosin patient counseling information|Patient Counseling Information]]''' | ||
Revision as of 20:00, 12 March 2014
| Doxazosin |
|---|
| Doxazosin®, Cardura® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Doxazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information about Doxazosin, click here.
Synonyms / Brand Names: DOXAZOSIN®, CARDURA®.
Overview
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an α1-selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH).
On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura XL.
It is an alpha-1 adrenergic receptor blocker that inhibits the binding of norepinephrine (released from sympathetic nerve terminals) to the alpha-1 receptors on the membrane of vascular smooth muscle cells. The primary effect of this inhibition is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.
Category
alpha-1 adrenergic receptor blocker
FDA Package Insert
Doxazosin®
Indications and Usage | Dosage and Administration | Contraindications | Warnings | Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages